BioSpace News Archive

Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering cell therapies targeting oncology and other diseases, today announced it has completed a Pre-Investigational New Drug (“Pre-IND”) meeting with the FDA.

Broadening its commitment to sustainability and corporate social value, Valent BioSciences LLC formally dedicated a new prairie park and solar field adjacent to its manufacturing facility in Osage, Iowa, on June 24.

Galderma, the emerging pure-play dermatology category leader, announced a private placement of approximately USD 1 billion for newly issued shares, from a group consisting of current shareholders, new investors, as well as management.

The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2023 of $1.13 per share on outstanding common stock.

AbbVie kicks off its eighth Week of Possibilities today with more than 14,000 employees volunteering in more than 50 countries and territories to serve local communities around the world.

Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”) announced today it has been selected to exhibit the Aurix® System, the first platelet rich plasma (PRP) device indicated for chronic diabetic wounds, at the Vizient Innovative Technology Exchange.

GeneDx (Nasdaq: WGS) today published a paper in Nature Methods, titled “Multiscale analysis of pangenomes enables improved representation of genomic diversity for repetitive and clinically relevant genes,” in which researchers developed a new computational tool, the PanGenome Research-Tool Kit (PGR-TK), for scalable analysis of clinically relevant genes that were previously too complex to analyze.

Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved CAMZYOS® (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules) for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (HCM) in adult patients.

Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that it has been added to the U.S. broad-market Russell 3000® Index at the conclusion of the Russell indexes annual reconstitution, effective upon the U.S. market open on Monday, June 26, 2023.

Abcam plc, a global leader in the supply of life science research tools, provides the following updates.